Common Side EffectsHematologic ToxicityNeutropenia may occur; regular complete blood count monitoring is required. Dose adjustment or treatment interr···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 115
Abemaciclib is an oral targeted anticancer drug belonging to the CDK4/6 inhibitor class. It is mainly used for the treatment of hormone receptor‑posit···【Read More】
Update: 2026-03-06Source: Haiou HealthViews: 123
Certain medications should not be used together due to safety concerns. Some drugs can alter the blood levels of others you are taking, which may incr···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 153
Grapefruit and grapefruit products may interact with cabozantinib and increase the risk of adverse side effects. Do not consume grapefruit products du···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 133
Seek emergency medical help immediately or call the Poison Help line.【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 158
Take the medication as soon as you remember. However, skip the missed dose if your next scheduled dose is in less than 12 hours. Do not take a double ···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 134
Cabozantinib is a broad-spectrum anticancer drug with multiple targets, inhibiting at least nine targets including MET, VEGFR1/2/3, ROS1, RET, AXL, NT···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 130
Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor developed by Exelixis in the United States. In November 2012, the FDA first a···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 126
On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 116
Cabozantinib is a broad-spectrum, multi-target anti-tumor drug developed by Exelixis Biopharmaceuticals, Inc. While most anti-tumor drugs target 1-3 t···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 125
Cabozantinib (Cabometyx), first approved by the FDA in 2012, is a non-specific tyrosine kinase inhibitor. It exerts its anti-tumor effect by targeting···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 116
On November 2, 2018, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved lorlatinib, a third-generation anaplastic lymphoma···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 121
On March 3, 2021, the U.S. Food and Drug Administration (FDA) approved Pfizer's supplemental New Drug Application (sNDA) for lorlatinib, expanding···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 123
Lorlatinib, the world's first third-generation ALK (anaplastic lymphoma kinase)/ROS1 tyrosine kinase inhibitor (TKI), was developed by Pfizer for ···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 120
Lorlatinib was approved for marketing in China by the National Medical Products Administration (NMPA) in April 2022 and has been included in the Natio···【Read More】
Update: 2026-03-05Source: Haiou HealthViews: 144
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos